Clik here to view.
武田与Seattle Genetics发布ADCETRIS® (brentuximab...
马萨诸塞州剑桥、日本大阪和华盛顿州博瑟尔 (美国商业资讯) — 武田药品工业株式会社(TSE:4502)和Seattle Genetics, Inc. (NASDAQ: SGEN)今天宣布，3期ECHELON-1临床试验达到主要终点，即修订版无进展生存(PFS)优于对照组，差异有统计学意义。ECHELON-1是随机、多中心试验，评估ADCETRIS (brentuximab...
View ArticleClik here to view.
Ipsen: Somatuline® Autogel® 120 mg Receives Japanese Approval for a New...
PARIS & TOKYO Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) and Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, today announced that Teijin Pharma has...
View ArticleClik here to view.
新基公司和百济神州在免疫肿瘤领域达成全球战略合作 共同在实体肿瘤领域推进PD-1抑制剂项目
美国新泽西州萨米特及中国北京 (美国商业资讯)– 新基公司(纳斯达克股票代码:CELG) 和 百济神州有限公司(纳斯达克股票代码:BGNE)宣布达成战略合作，共同开发和商业化反程序性细胞死亡蛋白（PD-1）抑制剂...
View ArticleClik here to view.
Celgene Corporation Enters Into Global Strategic Immuno-Oncology...
SUMMIT, N.J. & BEIJING Celgene Corporation (NASDAQ:CELG) and BeiGene, Ltd. (NASDAQ:BGNE) entered into a strategic collaboration to develop and commercialize BeiGene’s investigational...
View ArticleClik here to view.
Solasia Announces Approval of episil® (oral liquid) in Japan
TOKYO Solasia Pharma K.K. (TSE: 4597, Headquarters: Tokyo, Japan, President & CEO: Yoshihiro Arai, hereinafter “Solasia”) announced today that episil® (SP-03) has been approved for the...
View ArticleClik here to view.
Exelixis and Bristol-Myers Squibb Initiate Phase 3 Trial of Opdivo® in...
SOUTH SAN FRANCISCO, Calif. & NEW YORK Exelixis, Inc. (NASDAQ:EXEL) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the initiation of the phase 3 CheckMate 9ER trial to evaluate...
View ArticleClik here to view.
Data on Delivery of Tumor Treating Fields to be Presented at the 39th Annual...
ST. HELIER, Jersey Novocure (NASDAQ: NVCR) announced today that three oral presentations on Tumor Treating Fields (TTFields) will be given at the 39th Annual International Conference of the IEEE...
View ArticleClik here to view.
Moving Mountains for Multiple Myeloma Program to Take on Fourth Continent...
CRANBURY, N.J. A 20-person team, including patients with multiple myeloma, caregivers, healthcare providers and supporters, will set off to summit Japan’s iconic Mt. Fuji on July 19. The group is...
View ArticleClik here to view.
Abzena and Telix Sign Licence Agreement for Abzena’s Prostate-Specific...
CAMBRIDGE, England & MELBOURNE, Australia Abzena plc (AIM: ABZA, ‘Abzena’), the life sciences group providing services and technologies to enable the development and manufacture of...
View ArticleClik here to view.
Zymeworks and Daiichi Sankyo Announce Successful Achievement of a Research...
VANCOUVER, British Columbia, TOKYO and BASKING RIDGE, N.J. Zymeworks Inc. (“Zymeworks”), a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of...
View ArticleClik here to view.
Samsung Bioepis Announces RENFLEXIS™ (infliximab-abda) Now Available in the...
INCHEON, Korea Samsung Bioepis Co., Ltd. today announced the launch of RENFLEXIS™ (infliximab-abda), a biosimilar referencing Remicade® (infliximab), in the United States (US). RENFLEXIS™ was...
View ArticleClik here to view.
Dr. Reddy’s Q1 FY18 Financial Results
HYDERABAD, India Dr. Reddy’s Laboratories Ltd. (NYSE: RDY | BSE: 500124 | NSE: DRREDDY) today announced its consolidated financial results for the first quarter ended June 30, 2017 under...
View ArticleClik here to view.
Astellas Reports First Quarter FY2017 Financial Results
TOKYO Astellas Pharma Inc. (TOKYO:4503)(President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced the financial results for the first quarter of fiscal year 2017 (“FY2017”), ending March...
View ArticleClik here to view.
Takeda Reports 1st Quarter FY2017 Results
OSAKA, Japan Takeda Pharmaceutical Company Limited (TOKYO:4502): Underlying Revenue growth of 6.6% led by Takeda’s Growth Drivers Underlying Revenue grew +6.6% with growth across all regions (U.S....
View ArticleClik here to view.
武田薬品: 2017年度第1四半期の連結業績について
大阪 （ビジネスワイヤ） — 武田薬品工業株式会社 （東証：4502）： 実質的な売上収益の成長は6.6％の増収、成長ドライバーが牽引...
View ArticleClik here to view.
武田公布2017财年第一季度业绩
日本大阪 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited)(TOKYO: 4502)： 武田增长引擎带动基础营收增长 6.6% 基础营收增长+6.6%，各地区业务均有所增长（美国+13.5%、日本 +1.6%、欧洲与加拿大 +4.6%、 新兴市场...
View ArticleClik here to view.
Celltrion and Teva Announce U.S. FDA Acceptance of Biologics License...
INCHEON, Republic of Korea & JERUSALEM Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that the U.S. Food and Drug Administration (FDA) has accepted...
View ArticleClik here to view.
Saphetor and Supratech Leverage Genome Scale Analyses to Facilitate Precision...
LAUSANNE, Switzerland Saphetor SA, the Swiss precision-medicine company dedicated to advancing personalized diagnostics, announced today that it will provide its proprietary platform for analyzing...
View ArticleClik here to view.
Takeda and Molecular Templates Announce Multi-Target Research and Licensing...
OSAKA, Japan & AUSTIN, Texas Takeda Pharmaceutical Company Limited (TSE: 4502) and Molecular Templates, Inc. today announced a collaboration agreement for oncology drug discovery programs. The...
View ArticleClik here to view.
Swift Biosciences Announces New Industry-Leading Indexed Adapters for...
ANN ARBOR, Mich. Swift Biosciences, a leading provider of innovative library prep solutions for genomic sequencing, today announced the launch of Accel-NGS® 2S Indexed Adapters, a new portfolio of...
View Article